Bacillus coagulans ： Irritable Bowel Syndrome (IBS)
B エビデンス 少なくとも1件のランダム化試験がこれを支持しており、おおむね一貫した結果が得られています。Reduces abdominal pain, bloating, and diarrhea in IBS. Spore-forming nature provides excellent stability and gastric acid survival.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbacillus\u002Dcoagulans\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
Reduces abdominal pain, bloating, and diarrhea in IBS. Spore-forming nature provides excellent stability and gastric acid survival.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
効果: None
None
対象集団: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
n=61
4 weeks
Double-blind
Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal …
Dose: None
vs: Placebo
Outcome: Abdominal pain (NRS) and stool consistency (BSFS)
効果: None
P = 0.003 (pain); P = 0.035 (s
対象集団: Adults with diarrhoea-predominant IBS (IBS-D)
Randomized Controlled Trial
n=100
12 weeks
Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, …
Dose: None
vs: Control
Outcome: Pain outcomes
効果: None
P < .001
対象集団: IBS patients
Meta-Analysis
Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review …
Dose: Various probiotic strains/mixtures
vs: Placebo
Outcome: Outcome-specific efficacy ranking in IBS
効果: None
None
対象集団: Adults with IBS (RCTs)
Randomized Controlled Trial
12 weeks
Double-blind
The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in …
Dose: 20.5%
vs: placebo
Outcome: IBS symptom improvement
効果: None
p = 0.038
対象集団: Adults with IBS
Review
Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives.
Dose: None
vs: None
Outcome: colitis/IBD severity
効果: None
None
対象集団: None
Key Statistics
3
研究数
400
参加者数
↑
Positive
B
グレード
Referenced Papers
Journal of clinical …
2026
Beneficial microbes
2026
Medicine
2024
6 件の引用
Nutrients
2023
33 件の引用
Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives.
Review
Journal of oral …
2023
12 件の引用
International journal of …
2023
9 件の引用
Journal of clinical …
2023
9 件の引用
Medicine
2021
45 件の引用
Journal of dietary …
2021
33 件の引用
European journal of …
2020
20 件の引用
Scientific reports
2019
65 件の引用
Beneficial microbes
2019
45 件の引用
Beneficial microbes
2019
29 件の引用
Food & nutrition …
2018
162 件の引用
Beneficial microbes
2018
59 件の引用
Nutrition journal
2016
102 件の引用
European review for …
2014
33 件の引用
Gastroenterology and hepatology …
2014
Postgraduate medicine
2009
144 件の引用
Methods and findings …
2009
104 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1-2 billion CFU/day
- ibssupport:
- 2 billion CFU/day (GBI-30 6086 strain)
上限量： Well-tolerated up to 6 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 4 weeks | Positive | 61 |
| None | 12 weeks | Positive | 100 |
| Various probiotic strains/mixtures | -- | Positive | -- |
| 20.5% | 12 weeks | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
推奨摂取タイミング： With meals for optimal spore germination and colonization
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas during initial use (generally less than other probiotics due to spore form)
- ⚠ Occasional bloating
- ⚠ Rare loose stools
既知の相互作用
- ● Antibiotics (spore form is more resistant than vegetative probiotics, but spacing still recommended)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 6 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Bacillus coagulans help with Irritable Bowel Syndrome (IBS)?
Based on 3 studies with 400 participants, there is moderate evidence from clinical studies that Bacillus coagulans may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bacillus coagulans should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-2 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bacillus coagulans?
Reported side effects may include Mild gas during initial use (generally less than other probiotics due to spore form), Occasional bloating, Rare loose stools. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bacillus coagulans and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 3 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Irritable Bowel Syndrome (IBS)
References
- [1] Roman Maslennikov et al.. J Clin Med. 2026. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. doi:10.3390/jcm15031152 PubMed
- [2] K Sorensen et al.. Benef Microbes. 2026. Effects of a Bacillus subtilis HU58 and Heyndrickxia faecalis SC208 spore-forming probiotic formula on gastrointestinal health: results of a randomised, … doi:10.1163/18762891-bja00113 PubMed
- [3] Sohel S Shaikh et al.. Medicine (Baltimore). 2024. Role of Bacillus coagulans (Heyndrickxia coagulans)BCP92 in managing irritable bowel syndrome: A randomized, double-blind, multicenter, placebo-controlled clinical trial. doi:10.1097/MD.0000000000039134 PubMed
- [4] Peiwei Xie et al.. Nutrients. 2023. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. doi:10.3390/nu15173856 PubMed
- [5] Aysha Jebin A et al.. J Oral Biol Craniofac Res. 2023. Oral microbial shift induced by probiotic Bacillus coagualans along with its clinical perspectives. doi:10.1016/j.jobcr.2023.03.013 PubMed
- [6] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [7] Barbara Skrzydło-Radomańska et al.. J Clin Med. 2023. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel … doi:10.3390/jcm12144838 PubMed
- [8] Anil Kumar Gupta et al.. Medicine (Baltimore). 2021. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT … doi:10.1097/MD.0000000000023641 PubMed
- [9] Chiranjit Maity et al.. J Diet Suppl. 2021. Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus coagulans LBSC on Human Gut Microbiome Modulation. doi:10.1080/19390211.2020.1814931 PubMed
- [10] Khadijeh Abhari et al.. Eur J Nutr. 2020. Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? doi:10.1007/s00394-019-02060-y PubMed
- [11] Ratna Sudha Madempudi et al.. Sci Rep. 2019. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel … doi:10.1038/s41598-019-48554-x PubMed
- [12] Y Mu et al.. Benef Microbes. 2019. Bacillus coagulans and its applications in medicine. doi:10.3920/BM2019.0016 PubMed
- [13] Y Mu et al.. Benef Microbes. 2019. Bacillus coagulans and its applications in medicine. doi:10.3920/BM2018.0016 PubMed
- [14] Muhammed Majeed et al.. Food Nutr Res. 2018. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, … doi:10.29219/fnr.v62.1218 PubMed
- [15] M Ratna Sudha et al.. Benef Microbes. 2018. Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled … doi:10.3920/BM2017.0129 PubMed
- [16] Muhammed Majeed et al.. Nutr J. 2016. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled … doi:10.1186/s12937-016-0140-6 PubMed
- [17] R Urgesi et al.. Eur Rev Med Pharmacol Sci. 2014. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients … PubMed
- [18] Mehran Rogha et al.. Gastroenterol Hepatol Bed Bench. 2014. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. PubMed
- [19] Larysa Hun. Postgrad Med. 2009. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. doi:10.3810/pgm.2009.03.1984 PubMed
- [20] B J Dolin. Methods Find Exp Clin Pharmacol. 2009. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. doi:10.1358/mf.2009.31.10.1441078 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。